BSE filing, NSE: ALIVUS. Summary written from the filing by ALFA Finder's alert engine.
Alivus Life Sciences Ltd: key numbers
- Share price
- ₹1,471.90
- Market cap
- ₹18,100 Cr
- Revenue (annual)
- ₹2,552 Cr
- Net profit (annual)
- ₹564.5 Cr
- P/E (TTM)
- 27.0×Sector 42.0×
- Promoter holding
- 74.85%-0.02% QoQ
- FII holding
- 5.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alivus Life Sciences Ltd
All →Alivus Life Sciences Earnings Call Transcript: Key Takeaways
Alivus reported strong revenue growth driven by new products and CDMO traction, though margins were inflated by one-time income.
- Call
- Guides 11% growth
Alivus Life Sciences Employee Stock Options
Alivus Life Sciences allotted 1,95,833 equity shares to an employee who exercised ESOP options under its 2021 scheme. Paid-up capital rises to Rs. 24.59 Crore.
Alivus Life Sciences Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹6,820 Mn (+16.0% YoY), EBITDA ₹2,851 Mn (41.8% margin), PAT ₹1,968 Mn (+51.3% YoY). Non-GPL growth and CDMO pickup drove results.
Alivus Life Sciences Results Update
Alivus Life Sciences reported Q2FY27 revenue of Rs. 6,820 Mn (up 16.0% YoY) and PAT of Rs. 1,968 Mn in a press release. Investors see record EBITDA margins of 41.8% and capex progress at Solapur and Taloja.
Alivus Life Sciences Q2 FY27 Results: Net Profit ₹196.7 Cr, Up 51.3% YoY
Alivus Life Sciences Ltd reported revenue from operations of ₹682 Cr (+16.0% YoY) and net profit of ₹196.7 Cr (+51.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹196.7 Cr · +51.3% YoY
Alivus Life Sciences Board Meeting Date
Alivus Life Sciences Ltd has scheduled a Board Meeting on October 29, 2026, to consider and approve its unaudited financial results for the period ended September 30, 2026.
Other business update announcements
All →Skyways Air Services Business Update
Skyways Air Services renewed its Global Annual Agreement with Qatar Airways for one year. The agreement's size is not quantifiable, so no value is assigned.
- From
- Qatar Airways Group Q.C.S.C.
- Execution
- 1 year from effective date 1 January 2026
Zydus Lifesciences Business Update
Zydus Lifesciences' subsidiary presented Phase 2b trial data for investigational saroglitazar in MASH at AASLD 2026. The drug showed higher steatohepatitis resolution than placebo, but its safety and effectiveness for this use are not yet established.
Rajshree Sugars & Chemicals Business Update
Rajshree Sugars reported October 2026 operational data for its three sugar units. Sugar sales were 17,849 MT, with no cane crushed during the month.
Fino Payments Bank Business Update
Fino Payments Bank's October 2026 update showed deposits crossing Rs 3,000 Crore for the first time. Loan referral disbursals rose 316% year-on-year to Rs 301 Crore.
Ugar Sugar Works Business Update
Ugar Sugar Works has informed the exchanges that crushing for the 2026-27 season started at its Ugar Unit on 06 Nov 2026. Crushing will ramp up to full capacity over time.
Aarti Drugs Business Update
Aarti Drugs disclosed that the US FDA inspected its subsidiary Pinnacle Life Science's Baddi plant on 2-6 November 2026 and issued three Form 483 observations. The company states there is no financial or operational impact.